8-K: Seres Therapeutics Reports Positive Q1 2025 Results and Advances SER-155 Development

Seres Therapeutics announced its Q1 2025 financial results, highlighting a net income driven by the Nestl payment and progress in advancing its SER-155 program for bloodstream infection prevention.

Summary

• Seres Therapeutics reported a net income of $32.7 million for Q1 2025, a significant improvement from the $32.9 million net loss in Q1 2024.
• This income was primarily driven by a $50 million installment payment from Nestl related to the VOWST asset sale.
• Research and development expenses decreased to $11.8 million from $19.5 million year-over-year, due to lower personnel expenses and reduced platform investments.
• General and administrative expenses also decreased to $11.9 million from $14.9 million in the same period.
• As of March 31, 2025, Seres had $58.8 million in cash and cash equivalents.
• The company expects its current cash, the upcoming Nestl payment in July 2025, and current operating plans to fund operations into the first quarter of 2026.
• Seres is focused on advancing SER-155, a live biotherapeutic for preventing bloodstream infections in allo-HSCT patients, and plans to submit a Phase 2 study protocol to the FDA in the coming weeks.
• The Phase 2 study is expected to target 248 participants and incorporate an adaptive design and an interim data analysis when approximately half of the enrolled participants have reached the primary endpoint.
• The company is also exploring strategic partnerships to support SER-155's clinical advancement and potential expansion into other patient populations.
• Seres is exploring options to advance the development of its investigational live biotherapeutics in inflammatory and immune diseases, including ulcerative colitis and Crohns disease.
• On April 21, 2025, Seres effected a 1-for-20 reverse stock split of its common stock.
• On May 6, 2025, the Company was notified by the Nasdaq Listing Qualifications staff that it has regained compliance with the Nasdaq Bid Price Requirement.

Sentiment

Score: 7

Explanation: The document presents a positive outlook with improved financial results and progress in SER-155 development, but also acknowledges the need for additional funding and potential risks.

Positives

• Seres achieved net income in Q1 2025, a significant turnaround from the previous year.
• The company has a clear plan to advance SER-155 through a Phase 2 study.
• SER-155 has shown promising Phase 1b results, including a 77% relative risk reduction in bloodstream infections.
• Seres has a cash runway into Q1 2026, providing financial stability for ongoing operations.
• The company is actively pursuing a strategic partnership to further develop SER-155.
• Seres regained compliance with the Nasdaq Bid Price Requirement.

Negatives

• The company requires additional capital to support the SER-155 Phase 2 study.
• The company has incurred significant losses, are not currently profitable and may never become profitable.
• The expected payments from the VOSWT sale are subject to risks and uncertainties.
• The company may not be able to realize the anticipated benefits of the VOWST sale, and may face new challenges as a smaller, less diversified company.

Risks

• Seres needs additional funding to support the SER-155 Phase 2 study.
• The company's future success depends on the successful development and commercialization of SER-155.
• The company faces risks associated with clinical trials, regulatory approvals, and market competition.
• The company may not be able to secure a partnership and/or generate or obtain additional capital or financing.
• The company may face new challenges as a smaller, less diversified company.

Future Outlook

Seres plans to submit a Phase 2 study protocol for SER-155 to the FDA in the coming weeks and is seeking a strategic partnership to support its development. The company expects to fund operations into Q1 2026.

Management Comments

• Advancing SER-155 through the next stage of development remains our top corporate priority, and we are making significant progress toward initiating the next clinical study, said Eric Shaff, President and Chief Executive Officer of Seres.
• The clinical results generated to date underscore the potential of SER-155 to redefine the standard of care for allo-HSCT recipients and other vulnerable patients at risk of bloodstream infections addressing a significant unmet medical need and representing substantial commercial opportunities.
• Guided by recent constructive FDA feedback and our aim to rapidly obtain clear and actionable SER-155 clinical results, we are preparing for a well-powered, placebo-controlled Phase 2 study, with a planned interim analysis.

Industry Context

Seres is focused on live biotherapeutics, a novel approach to treating diseases by modulating the microbiome. The company's lead candidate, SER-155, targets bloodstream infections in vulnerable patients, an area of significant unmet medical need. The company's previous success with VOWST validates the potential of this approach.

Comparison to Industry Standards

• The 77% relative risk reduction in bloodstream infections observed in the SER-155 Phase 1b study is a promising result compared to existing standards of care, which often rely on antibiotics and have limitations due to increasing antibiotic resistance.
• Prevymis is increasingly used for viral infection prophylaxis (e.g., allo-HSCT and solid organ transplant populations).
• Prevymis had $785M 24 WW sales (~30% growth over '23).
• The overall cost of allo-HSCT is high (~$400K US year 1 allo-HSCT costs).
• Transplant-related complications (e.g., infections) raise cost by ~$180K.

Stakeholder Impact

• Shareholders: The improved financial results and progress in SER-155 development are positive for shareholders.
• Patients: SER-155 has the potential to improve outcomes for patients at risk of bloodstream infections.
• Employees: The company's focus on SER-155 provides clarity and direction for employees.
• The VOWST asset sale provided capital to support pipeline advancement and resulted in a more streamlined, focused organization.

Next Steps

• Submit a Phase 2 study protocol for SER-155 to the FDA in the coming weeks.
• Continue seeking a strategic partnership to support SER-155 development.
• Present additional SER-155 clinical results at the ASCO 2025 conference.
• Receive the $25 million installment payment from Nestl in July 2025.

Key Dates

Keywords

SER-155, bloodstream infections, allo-HSCT, live biotherapeutics, clinical trial, Nestl, VOWST, FDA, Phase 2, partnership, reverse stock split, Nasdaq